As per MRFR analysis, the US Mastitis Market Size was estimated at 4.96 (USD Billion) in 2023. The US Mastitis Market Industry is expected to grow from 5.5(USD Billion) in 2024 to 9.5 (USD Billion) by 2035. The US Mastitis Market CAGR (growth rate) is expected to be around 5.094% during the forecast period (2025 - 2035).
The US Mastitis Market is experiencing noteworthy trends, driven by a growing awareness of animal health and optimal dairy production. Key market drivers include the increasing demand for high-quality milk and dairy products. As consumers prioritize nutritional value, dairy farmers are investing in better herd management practices, which directly influences the need for effective mastitis treatment solutions.
Additionally, the rising prevalence of mastitis in dairy cattle has prompted a shift towards innovative solutions to prevent and manage this condition. Opportunities in the US Mastitis Market are expanding, particularly as the dairy industry focuses on sustainability and animal welfare. This shift opens doors for new products that offer both efficacy and environmental safety, including alternative therapies and preventative measures.
The integration of technology, such as monitoring systems and data analytics, provides dairy farmers with tools to identify early signs of mastitis, further enhancing herd health and productivity. Recent trends highlight an increasing collaboration between veterinary services and dairy producers, which enhances the overall approach to mastitis management. Education and training initiatives are also underway, aimed at raising awareness among farmers about the importance of timely intervention and proper milking procedures.
Consequently, this collaborative approach not only advances treatment pathways but also fosters a culture of proactive health management within the dairy industry. The convergence of technology, education, and demand for quality dairy reinforces the dynamic development of the US Mastitis Market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The US Mastitis Market Industry is significantly driven by the increasing incidence of mastitis in dairy cattle. According to the United States Department of Agriculture (USDA), mastitis accounts for around 40% of all dairy cow health issues, with each case resulting in considerable financial loss for farmers due to decreased milk production and increased veterinary costs.
Research has indicated that the prevalence of mastitis in dairy herds can lead to economic losses ranging from 200 to 300 USD per cow annually. This emphasizes the necessity for effective treatment solutions and preventative measures, which in turn promotes growth in the US Mastitis Market.
As producers are becoming more aware of the impact of mastitis on profitability, there is an increasing demand for innovative therapies, such as antimicrobial drugs and vaccination programs, to tackle the problem. The increasing focus on herd health management by established organizations like the American Association of Bovine Practitioners has also heightened industry awareness and awareness regarding the significance of managing mastitis.
The US Mastitis Market Industry is being propelled by advancements in diagnostic technologies and treatment solutions for mastitis. The development of rapid diagnostic tests enables farmers and veterinarians to quickly identify mastitis pathogens, leading to timely and appropriate treatment interventions. The introduction of novel treatment protocols utilizing antimicrobials and alternative therapies is transforming the management practices for mastitis.
Prominent agricultural technology firms have invested heavily in Research and Development (R&D) for innovative products, resulting in effective solutions that are driving market growth. For instance, the National Dairy FARM (Farmers Assuring Responsible Management) program emphasizes the need for evidence-based practices in managing mastitis, including the implementation of improved diagnostic methodologies.
This has encouraged dairy producers to adopt new technologies, enhancing overall herd health and increasing production efficiency.
The US Mastitis Market Industry benefits from the growing awareness of animal welfare, leading to increased scrutiny of dairy farming practices. According to the American Veterinary Medical Association (AVMA), consumers are increasingly concerned about the humane treatment of farm animals, influencing the dairy industry's practices and encouraging farmers to adopt better management practices that prevent mastitis.
This rising demand for ethically produced dairy products has prompted farmers to implement animal welfare programs that monitor and improve cow health, thereby reducing complications associated with mastitis. As a result, there is a rising market for preventative health measures, educational programs, and treatments that align with animal welfare standards, ultimately fostering growth in the US Mastitis Market.
The US Mastitis Market has demonstrated significant segmentation based on the type of mastitis, with each category addressing unique pathogens and treatment demands in the dairy industry. Contagious Mastitis is a leading type known for high transmission rates among dairy herds, primarily caused by bacteria such as Streptococcus agalactiae and Staphylococcus aureus. This presents challenges for livestock management, requiring strict biosecurity measures and effective milking hygiene practices.
Environmental Mastitis, often linked to pathogens found in the cow's environment, particularly thrives in less sanitary conditions, making control imperative for herd health and productivity. The rising focus on improved farm management practices and cleaner living conditions is crucial in reducing instances of this type. Opportunist Mastitis, while typically less common, can occur due to various bacteria acting on compromised health; thus, monitoring cow health remains paramount to minimizing these occurrences.
Non-Infectious Mastitis distinguishes itself through factors such as trauma or chemical irritants rather than infections, highlighting the necessity for comprehensive management strategies that emphasize cow comfort and welfare. Infectious Mastitis, as a broad classification, underscores both environmental and contagious infections, where the need for robust testing and results-driven treatment protocols stands out.
As these types reveal the diverse causes and implications of mastitis, understanding their characteristics is essential for the US Mastitis Market statistics, guiding research and development efforts aimed at enhancing dairy health and industry standards. Overall, the segmentation by type is not only fundamental for tailoring interventions but is also a driver for advancements in treatment and prevention efforts, establishing a solid foundation for the growth and evolution of the market. Each type contributes to the overarching goal of optimizing herd health, enhancing milk production efficiency, and ultimately fostering a sustainable dairy industry environment within the US.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Treatment segment of the US Mastitis Market plays a crucial role in addressing this prevalent condition among dairy livestock. With the increasing focus on animal health and productivity, Antibiotics remain a primary choice for veterinarians due to their effectiveness in combating bacterial infections, which are a significant cause of mastitis in dairy cattle.
Vaccines are gaining traction as a preventive measure, aiming to bolster the immune response in herds and reduce the incidence of mastitis, thereby enhancing herd health and economic returns for farmers. Pain Relievers are essential for managing discomfort in affected animals, improving their overall welfare and productivity. The growing awareness of mastitis impacts on milk quality and economic losses further drives the demand within this segment.
Overall, innovations and advancements in treatment methodologies are observed, contributing positively to the market growth, making it a pivotal area of focus within the US Mastitis Market landscape.
The End User segment of the US Mastitis Market is crucial for understanding the distribution of veterinary services and healthcare interventions tailored for mastitis management. Veterinary Centers play a significant role in providing specialized diagnoses and treatments, catering primarily to livestock and dairy farmers who face challenges related to mastitis. These centers are equipped with advanced technologies and skilled professionals to ensure effective disease management, significantly impacting milk production quality and herd health.
Additionally, Hospitals and Clinics are pivotal for handling more complex cases, providing a range of diagnostic tools, therapies, and surgical options that help mitigate mastitis in both large and small agricultural operations. The growing adoption of preventive measures and frequent consultations in these end-user facilities is vital for controlling mastitis, leading to improved animal welfare and economic benefits for farmers.
As the US dairy industry emphasizes milk quality and health standards, the importance of these end user categories continues to grow, making them indispensable in the ongoing fight against mastitis. Overall, the insights reveal that addressing mastitis through these platforms is integral for sustaining productivity and enhancing agricultural practices across the nation.
The US Mastitis Market has gained significant attention in recent years due to the increasing prevalence of mastitis among dairy cattle, which necessitates effective management solutions to ensure animal health and optimize milk production. As dairy farms continue to intensify and embrace technology, the competition in this market has become aggressive. Numerous players are innovating their product offerings, ranging from antibiotics and anti-inflammatory agents to diagnostic tools and prevention strategies.
This competitive landscape is shaped by the demand for sustainable practices, stringent regulatory policies, and a growing awareness of animal welfare. As a result, companies are continuously evolving their strategies to enhance their market share and improve overall product efficacy in addressing mastitis. Within this competitive realm, Genus has established a strong presence in the US Mastitis Market.
This company is recognized for its dedication to agricultural biotechnology and its role in advancing genetic solutions aimed at enhancing livestock productivity and health. Genus’s strengths lie in its innovative breeding technologies and robust research and development initiatives, which enable it to provide valuable genetic assets tailored for dairy operations. By leveraging its expertise in genomics, Genus has been able to create livestock that is less susceptible to mastitis, thereby improving disease resistance in dairy herds.
This strategic focus on genetic health and resilience has positioned Genus favorably against competitors, allowing it to cater to the evolving needs of dairy farmers in the US. Vetoquinol also plays a significant role in the US Mastitis Market, offering a range of veterinary products and services focused on promoting animal health. Key offerings from Vetoquinol include anti-mastitis treatments, milking hygiene solutions, and nutritional supplements designed to enhance the wellbeing of dairy cattle and reduce the incidence of mastitis.
The company boasts a well-established market presence, supported by an extensive distribution network that ensures product accessibility to dairy farmers. Vetoquinol's strengths are highlighted by its strong research foundation, commitment to innovation, and a focus on customer education regarding best practices in mastitis management. Additionally, Vetoquinol has engaged in strategic collaborations and acquisitions, enhancing its product portfolio and fostering advancements in veterinary care within the US market. The combination of these attributes solidifies Vetoquinol’s position as a key player in addressing the challenges posed by mastitis among dairy herds in the region.
Recent developments in the US Mastitis Market indicate a dynamic and evolving landscape, with continued focus on combating this significant dairy cattle health issue. Companies such as Zoetis, Merck Animal Health, and Elanco Animal Health have been actively engaging in Research and Development to enhance treatment options for mastitis, which is critical for maintaining herd health and productivity.
In August 2023, Genus announced a partnership with Alltech for the implementation of microbiome-based solutions aimed at reducing cases of mastitis. Reports also indicate a growing trend towards the use of advanced probiotics and vaccines to address mastitis, showcasing innovations from firms like Vetoquinol and Boehringer Ingelheim.
In terms of financial movement, the valuation of companies involved in the US Mastitis Market has shown considerable growth due to rising awareness of animal health and welfare. Over the past few years, the market has witnessed a steady increase in investments and mergers, with notable activities reported, such as Westway Feed Products seeking to enhance its product line through a strategic acquisition in July 2022.
Additionally, the Agricultural Research Service has implemented programs aimed at improving early detection and treatment methodologies, further solidifying the proactive approach within the market.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 4.96(USD Billion) |
| MARKET SIZE 2024 | 5.5(USD Billion) |
| MARKET SIZE 2035 | 9.5(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.094% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Genus, Vetoquinol, Milk Specialties Global, Westway Feed Products, DeLaval, Zoetis, Merck Animal Health, Elanco Animal Health, Boehringer Ingelheim, Alltech, Cegelec, Phibro Animal Health, Lallemand, Huvepharma |
| SEGMENTS COVERED | Type, Treatment, End User |
| KEY MARKET OPPORTUNITIES | Telemedicine for remote diagnosis, Advanced diagnostic tools development, Increased organic dairy demand, Innovative treatment solutions, Education and training programs |
| KEY MARKET DYNAMICS | Increasing dairy production, Rising healthcare awareness, Advanced treatment technologies, Government support initiatives, Growing demand for quality milk |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The US Mastitis Market is expected to be valued at 5.5 billion USD in 2024.
By 2035, the US Mastitis Market is projected to reach a valuation of 9.5 billion USD.
The expected Compound Annual Growth Rate (CAGR) for the US Mastitis Market from 2025 to 2035 is 5.094 percent.
In 2024, infectious mastitis holds the largest market value at 2.5 billion USD.
The market segment for contagious mastitis is expected to grow from 1.2 billion USD in 2024 to 2.1 billion USD by 2035.
Key players in the US Mastitis Market include Genus, Zoetis, Merck Animal Health, and Elanco Animal Health.
The market size for environmental mastitis is projected to reach 1.9 billion USD by 2035.
The US Mastitis Market faces challenges such as increasing antibiotic resistance and the need for innovative treatment solutions.
Opportunities for growth in the US Mastitis Market include advancements in dairy farming technologies and increased awareness of animal health.
Yes, the market for non-infectious mastitis is expected to increase to 1.5 billion USD by 2035.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
